| 傅媛媛 肖青△ 刘芬 吴昊 罗国平.Hyper-CVAD/MA治疗复发或难治性弥漫大B 细胞淋巴瘤的临床研究[J].现代生物医学进展英文版,2016,16(10):1894-1897. |
| Hyper-CVAD/MA治疗复发或难治性弥漫大B 细胞淋巴瘤的临床研究 |
| The Efficacy and Safety of Hyper-CVAD/MA Regimen in the Treatment ofRecurrent or Refractory Diffuse Large B-cell Lymphoma |
| |
| DOI： |
| 中文关键词: 弥漫大B细胞淋巴瘤 复发/难治 Hyper-CVAD/MA 方案 |
| 英文关键词: Diffuse large B-cell lymphoma Recurrent Refractory Hyper-CVAD/MA regimen |
| 基金项目:重庆市卫生局重点项目课题（2013-1-013） |
|
| Hits: 930 |
| Download times: 0 |
| 中文摘要: |
| 目的：探讨Hyper-CVAD/MA方案治疗复发或难治弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma，DLBCL)的疗效及安
全性。方法：观察26 例经系统化疗后复发或难治的DLBCL患者接受Hyper-CVAD/MA 方案化疗，21-28 天为1 周期，连续2 个周
期评价疗效及安全性，分析生存情况。结果：全组26 例患者中，总有效率为46.15 %，其中完全缓解(complete remission，CR)3 例
(11.54 %)，部分缓解(partial remission，PR) 9例(34.61 %)，全组患者中位生存时间为10(2-25)个月，1 年和2 年总生存率分别为
28.57 %、14.29 %。不良反应主要表现为III-IV 度骨髓抑制及继发的肺部感染，其他包括胃肠道反应、口腔炎、肝功能异常等。结论：
Hyper-CVAD/MA 治疗复发难治DLBCL有一定的疗效，且患者可耐受，可作为二线方案的一个选择。 |
| 英文摘要: |
| Objective:To evaluate the clinical efficacy and safety of Hyper-CVAD/MA regimen in patients with recurrent or
refractory diffuse large B-cell lymphoma (DLBCL).Methods:All 26patients with recurrent or refractory DLBCL were treated with
Hyper-CVAD/MA regimen after routine treatment. 21-28 days consisted of one cycle, and the therapeutic efficacy and adverse effect
were observed after two cycles.Results:In 26 cases, the overall response rate was 46.15 %. Three patients (11.54 %) achieved a complete
remission and9 (34.61 %) achieved a partial remission. The median time of the OS (overall survival) was 10 months. The one-year OS
rate and two-year OS rate were 28.57 % and 14.29 %, respectively. Myelosuppression and infection were the major adverse reaction.
Other side effects included gastroenteric reactions, oral mucosa inflammation, damage of live function was also observed.Conclusion:Hyper-CVAD/MA regimen can achieve a satisfied result in the treatment of recurrent or refractory DLBCL, and the toxicity was
tolerable. |
|
View Full Text
View/Add Comment Download reader |
| Close |
